Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01163032 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder
A Phase 3 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 136
- Enrollment target
NCT01163032 is a Phase 3 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 136 participants.
The verdict
NCT01163032, a Phase 3 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of a six month double-mask treatment of tasimelteon or placebo in male and female subjects with Non-24-Hour Sleep-Wake Disorder
Interventions
- DRUG Placebo
- DRUG tasimelteon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01163032
The ClinicalTrials.gov registry entry for NCT01163032 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01163032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01163032 about?
NCT01163032 is a clinical study titled "Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder". The purpose of this study is to evaluate the efficacy and safety of a six month double-mask treatment of tasimelteon or placebo in male and female subjects with Non-24-Hour Sleep-Wake Disorder
What is the current status of trial NCT01163032?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2010-08. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01163032?
The interventions under investigation include: Placebo (DRUG), tasimelteon (DRUG).
Who is sponsoring clinical trial NCT01163032?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.